{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:34Z","timestamp":1790398774601,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700530"],"award-info":[{"award-number":["81700530"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772187"],"award-info":[{"award-number":["81772187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971949"],"award-info":[{"award-number":["81971949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Project of China","award":["2017ZX10202202"],"award-info":[{"award-number":["2017ZX10202202"]}]},{"name":"National Science and Technology Major Project of China","award":["2018ZX10301202"],"award-info":[{"award-number":["2018ZX10301202"]}]},{"name":"National Science and Technology Major Project of China","award":["2017ZX10302201"],"award-info":[{"award-number":["2017ZX10302201"]}]},{"name":"Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program","award":["2017BT01S131"],"award-info":[{"award-number":["2017BT01S131"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Safe nucleos(t)ide analogue discontinuation in chronic hepatitis B (CHB) is an unmet need. We aimed to investigate whether combining hepatitis B virus (HBV) RNA and hepatitis B core\u2013related antigen (HBcrAg) could perform satisfactorily in predicting off-treatment outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The evaluation cohort included 127 hepatitis B e antigen (HBeAg)\u2013positive patients from a multicenter prospective trial who stopped telbivudine-based therapy after achieving HBeAg seroconversion and HBV DNA\u2005&amp;lt;\u200550 IU\/mL for\u2005&amp;gt;\u200548 weeks. As validation, 59 patients treated with entecavir or tenofovir before discontinuation were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At the end of treatment (EOT), HBV RNA and HBcrAg were significant independent predictors of the clinical relapse risk. In the evaluation cohort, no clinical relapse occurred among patients with negative HBV RNA and HBcrAg\u2005&amp;lt;\u20054 log10 U\/mL at EOT (low-risk group), whereas 46.8% patients with positive HBV RNA and HBcrAg\u2005\u2265\u20054 log10 U\/mL (high-risk group) experienced clinical relapse during 4-year posttreatment follow-up (P\u2005&amp;lt;\u2005.001); the corresponding incidences in the validation cohort were 0% and 69.4% (P\u2005&amp;lt;\u2005.001), respectively. More patients in the low-risk group achieved HBsAg loss than the other patients after treatment cessation (16.1% vs 1.3%, P\u2005=\u2005.002).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Combining HBV RNA and HBcrAg performed satisfactorily in predicting clinical relapse and HBsAg loss after treatment cessation in HBeAg-positive patients with CHB.<\/jats:p>\n                  <jats:p>The combination of hepatitis B virus RNA and hepatitis B core\u2013related antigen performed satisfactorily in predicting clinical relapse and hepatitis B surface antigen loss after stopping nucleos(t)ide analogue treatment among noncirrhotic hepatitis B e antigen\u2013positive patients with chronic hepatitis B and could be used to guide safe discontinuation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa136","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T20:08:06Z","timestamp":1584821286000},"page":"611-618","source":"Crossref","is-referenced-by-count":83,"title":["Combining Hepatitis B Virus RNA and Hepatitis B Core\u2013Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen\u2013Positive Patients With Chronic Hepatitis B"],"prefix":"10.1093","volume":"222","author":[{"given":"Rong","family":"Fan","sequence":"first","affiliation":[{"name":"State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deming","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[{"name":"Eighth People\u2019s Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[{"name":"Hepatology Unit, No. 1 Hospital affiliated to Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maorong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, 81st PLA Hospital, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Zhejiang University First Affiliated Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, West China Hospital, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefan","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Tangdu Hospital, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaobo","family":"Wu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Chronic Hepatitis B Study Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"2020072311065633600_CIT0001","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"2020072311065633600_CIT0002","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"2020072311065633600_CIT0003","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"2020072311065633600_CIT0004","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","author":"Giersch","year":"2017","journal-title":"J Hepatol"},{"key":"2020072311065633600_CIT0005","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J Hepatol"},{"key":"2020072311065633600_CIT0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucleos(t)ide analogue therapy","volume":"18","author":"Fan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020072311065633600_CIT0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2020072311065633600_CIT0008","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/hep.26885","article-title":"The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study","volume":"59","author":"Sun","year":"2014","journal-title":"Hepatology"},{"key":"2020072311065633600_CIT0009","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"2020072311065633600_CIT0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/jix025","article-title":"Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B: a prospective stop study","volume":"215","author":"Cao","year":"2017","journal-title":"J Infect Dis"},{"key":"2020072311065633600_CIT0011","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","article-title":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients","volume":"48","author":"Tsuge","year":"2013","journal-title":"J Gastroenterol"},{"key":"2020072311065633600_CIT0012","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Jung","year":"2016","journal-title":"J Gastroenterol"},{"key":"2020072311065633600_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hepr.12269","article-title":"JSH guidelines for the management of hepatitis B virus infection","volume":"44","author":"Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology","year":"2014","journal-title":"Hepatol Res"},{"key":"2020072311065633600_CIT0014","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"2020072311065633600_CIT0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"2020072311065633600_CIT0016","article-title":"Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy","author":"Carey","year":"2019","journal-title":"Hepatology"},{"key":"2020072311065633600_CIT0017","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.clinre.2018.10.020","article-title":"Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy","volume":"43","author":"Wang","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa136\/32964747\/jiaa136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/4\/611\/33524469\/jiaa136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/4\/611\/33524469\/jiaa136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T15:10:03Z","timestamp":1595517003000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/4\/611\/5811444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,3,25]]},"published-print":{"date-parts":[[2020,7,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa136","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,15]]},"published":{"date-parts":[[2020,3,25]]}}}